Compare Smith & Nephew plc (SNN) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Invesco S&P 500 Low Volatility ETF trades at $74.1. The key difference: Smith & Nephew plc pays a 2.85% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | SPLV | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | — |
52-Week High | $38.53 | $77.97 |
52-Week Low | $27.80 | $70.30 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $74.55, down 0.25% on the day, with a bearish technical signal driven by moving averages. The ETF has underperformed the S&P 500, returning 5% versus 17%, due to sector overweights in Utilities, Real Estate, and Financials. Recent news highlights its role as a stability-focused option amid market volatility, with dividends scheduled for mid-2026.
The outlook for SPLV is neutral to cautious, offering defensive exposure but facing headwinds from unappealing growth-adjusted valuations and sector concentration risks. Investment appeal hinges on market volatility trends, while risks include prolonged underperformance if low-volatility sectors lag in a growth-oriented market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
